This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Healthcare Europe

Press Releases

Take a look at a selection of our recent media coverage:

Potential drug candidates for incurable brain tumour in children identified through AI

27th September 2021

Hopes of a possible drug treatment for an incurable brain tumour in children has come from the use of an AI enhanced tool.

Diffuse intrinsic pontine glioma (DIPG) is a childhood brain tumour that is both highly aggressive and difficult to treat. It is an essentially incurable brain tumour with an incidence of 1 to 2 cases per 100,000 and occurs mainly between the ages of 6 to 9 years with an estimated median overall survival of 11.2 months. The lack of progress with treatments was highlighted in a 2020 review of trials in DIPG which commented on how there was a consistency of non-significant improvement to prognosis in these trials.

The underlying cause of this incurable brain tumour is thought to be related to genetic mutations, one of which occurs in the ACVR1 gene that encodes the serine/threonine kinase, ALK2 and is present in around 21% of DIPG samples. There are currently no known treatments for DIPG with this mutation although some data from patient-derived in vitro tumour models suggests that inhibition of ALK2 reduces cell viability. The clinical development of ALK2 inhibitors is therefore a potentially important avenue to explore. Nevertheless, drug discovery can be a time-consuming process although one recent approach which is becoming used more frequently, is big data analytics and in particular, the use of artificial intelligence (AI) systems.

The use of AI for drug discovery essentially seeks to explore whether currently available treatments can be repurposed and this was the approach taken by a team from the Division of Molecular Pathology, Institute of Cancer Research, London, UK, to identify potential drug candidates for ACVR1-mutant DIPG cases. The researchers turned to BenevolentAI which makes use of a knowledge graph that incorporates millions of documents and information on diseases, biological tissues, genes and proteins. Using BenevolentAI, the researchers looked for compounds that were likely to have an inhibitory effect on the ALK2 protein but also one that could penetrate into the central nervous system.


In their search for a treatment for the incurable brain tumour, one likely candidate emerged: vandetanib and which is already approved for symptomatic medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. However, drug levels of vandetanib in the cerebrospinal fluid have been found to be low, and a search for compounds that would enable vandetanib to remain within the brain long enough to induce a therapeutic effect uncovered everolimus. The researchers found that in vivo studies in mice demonstrated that combining vandetanib with everolimus, which is again approved for several cancers, increased the brain concentration of vandetanib by 56%.

In further animal studies, the combination extended survival by 14 % compared to controls and also significantly reduced tumour burden over the course of a four week treatment. To examine the clinical value in patients, the researchers used both drugs in four children with DIPG due to ACVR1 mutations.

The study lead, Professor Chris Jones, said “DIPG is a rare and aggressive childhood brain cancer, and survival rates have not changed over the past 50 years, so we desperately need to find new treatments for this disease.”

The authors concluded by calling for an early phase clinical trial to determine the utility of this approach for children with this incurable brain tumour.


Carvalho DM et al. Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma. Cancer Discovery 2021.

Artificial intelligence appears to be less accurate than radiologists in breast cancer screening

23rd September 2021

Breast cancer screening using artificial intelligence systems has been found, in the majority of cases, to be less accurate than a radiologist.

Globally, in 2020, there were an estimated 2.3 million women diagnosed with breast cancer leading to 685,000 deaths. Fortunately, improvements in survival over recent decades have been attributed to population-based breast cancer screening with mammography. In fact, a recent UK study suggested that screening reduces cancer mortality by 38% among women screened at least once.

The use of artificial intelligence (AI) systems for image recognition in breast cancer screening could lead to improvements in the detection of cases, either as a standalone system or as an aid to radiologists. Indeed, there is some evidence to support the value of AI with one retrospective analysis of an AI screening algorithm concluding that it showed better diagnostic performance than a radiologist. Nevertheless, in a 2019 review, it was concluded that while AI systems have good accuracy for breast cancer detection, methodological concerns and evidence gaps exist that limit translation into clinical breast cancer screening settings.

In light of these concerns, a team from the Division of Health Sciences, University of Warwick, UK, were commissioned by the UK National Screening Committee to undertake a systematic review to determine whether there was sufficient evidence to support the introduction of AI for mammographic image analysis in breast screening. They conducted literature searches up to May 2021 and included studies that reported the test accuracy of AI algorithms either alone or in combination with radiologists, to detect breast cancer in digital mammograms in screening practice or in test sets. The team included cancer confirmed by histological analysis of biopsy samples in cases where women were referred for further tests after screening as the reference standard or from symptomatic presentation during follow-up.

The review identified a total of 12 studies including 131,822 women undergoing breast cancer screening. In studies with a standalone AI system, the algorithm calculated a cancer risk score, categorising women at either high (recall) or low (no recall) risk. When used to assist the radiologist, the AI system simply provided a level of suspicion. In two large retrospective studies including 76,813 women, that compared the AI system with the clinical decisions of a radiologist, 96% of systems were less accurate than a single radiologist and all were less accurate than a double read.
Overall, the authors reported considerably heterogeneity in study methodology, some of which resulted in high concerns over the risk of bias and applicability. In their study, they commented that “evidence is insufficient on the accuracy or clinical effect of introducing AI to examine mammograms anywhere on the screening pathway”.

In the conclusion, the authors noted how AI systems for breast cancer screening are a long way from having the quality and quantity required for implementation into clinical practice.

Freeman K et al. Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy. BMJ 2021

AI predicts COVID-19 status before a PCR test

9th October 2020

Current testing for COVID-19 relies on a PCR test using nasopharyngeal swabs although results can take up to 48 hours and sometimes even longer.

Now a team from Weill Cornell Medicine, New York, has created an artificial intelligence (AI) system that can use routine test data results to determine if a patient has COVID-19. Normally, clinicians order a battery of blood tests in addition to a PCR test, including routine laboratory tests and a chest X-ray and these results are generally available within 1 – 2 hours. Researchers therefore hypothesised if the results of the routine laboratory test could be used to predict if someone was infected with COVID-19 without the PCR test. The included patient demographics such as age, sex, race into a machine learning model and incorporated the results for 27 routine tests. The laboratory results were made available two days before the PCR test result. The dataset included a total of 5893 patients admitted to hospital between March and April 2020 and they excluded individuals under 18 years of age and those who PCR result was inconclusive and patients without laboratory test results within two days prior to the PCR test.

A total of 3356 patients who were tested for COVID-19 were included with a mean age of 56 years of whom, 1402 were positive and 54% emergency department admissions. Using a machine learning technique known as a gradient boosting decision tree, overall, the algorithm identified COVID-19 positivity with a sensitivity of 76% and a specificity of 81%. However, limiting the analysis to emergency department patients, increased the sensitivity to 80% and the specificity to 83%. Moreover, the algorithm correctly identified those who had a negative COVID-19 test result. A recognised limitation was the testing was specific those admitted to hospital with moderate to severe disease and thus requires further work to identify milder cases.

Nevertheless, the authors concluded that their algorithm is potentially of value in identifying whether patients have COVID-19 before they receive the results of a PCR test.

Yang HS et al. Routine laboratory blood tests predict SARS-CoV-2 infection using machine learning. Clin Chem 2020;